CRISPR Therapeutics AG (LON:0VRQ)

Market Cap	3.89B
Revenue (ttm)	29.16M
Net Income (ttm)	-298.49M
Shares Out	n/a
EPS (ttm)	-3.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,512
Average Volume	11,246
Open	56.68
Previous Close	57.26
Day's Range	53.40 - 56.68
52-Week Range	30.04 - 71.12
Beta	n/a
RSI	49.26
Earnings Date	Aug 5, 2025

About bluebird bio

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, a...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2013
• Employees: 393
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0VRQ

Financial Performance

In 2024, CRISPR Therapeutics AG's revenue was $37.31 million, a decrease of -89.95% compared to the previous year's $371.21 million. Losses were -$366.25 million, 138.4% more than in 2023.

Financial numbers in CAD